These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36980941)

  • 1. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
    van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
    Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.
    Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M
    Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia.
    Chaudhry A; Trinder M; Vesely K; Cermakova L; Jackson L; Wang J; Hegele RA; Brunham LR
    Circ Genom Precis Med; 2023 Apr; 16(2):e003887. PubMed ID: 36960729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
    Pirillo A; Catapano AL; Norata GD
    Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD.
    Srivastava RAK
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
    Bajaj A; Cuchel M
    Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
    Bajaj A; Cuchel M
    J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation in a large cohort of pediatric patients with heterozygous and homozygous familial hypercholesterolemia.
    Reijman MD; Defesche JC; Wiegman A
    Curr Opin Lipidol; 2023 Dec; 34(6):287-295. PubMed ID: 36752612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
    Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E
    Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypical, Clinical, and Molecular Aspects of Adults and Children With Homozygous Familial Hypercholesterolemia in Iberoamerica.
    Alves AC; Alonso R; Diaz-Diaz JL; Medeiros AM; Jannes CE; Merchan A; Vasques-Cardenas NA; Cuevas A; Chacra AP; Krieger JE; Arroyo R; Arrieta F; Schreier L; Corral P; Bañares VG; Araujo MB; Bustos P; Asenjo S; Stoll M; Dell'Oca N; Reyes M; Ressia A; Campo R; Magaña-Torres MT; Metha R; Aguilar-Salinas CA; Ceballos-Macias JJ; Morales ÁJR; Mata P; Bourbon M; Santos RD
    Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):2508-2515. PubMed ID: 32757650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.
    Hamasaki M; Sakane N; Hara K; Kotani K
    J Clin Lab Anal; 2021 Nov; 35(11):e24056. PubMed ID: 34652028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
    Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
    Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD
    Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.